Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)Median OS of 14.8 months in patients who achieved MRD-negative CR/CRi First interim analysis for the BALLI-01 trial expected in Q4 2026 Eti-cel in r/r NHL (NATHALI-01) ORR of 86% and 57% CR rate (n=7)Development update to be presen ...

公司临床进展 - 公司宣布其两项研究摘要被美国血液学会2025年年会接受，将以海报形式展示[1] - 第一项海报提供在研产品eti-cel的研发更新，该产品是一种靶向CD20和CD22的同种异体双靶点CAR-T，正在NATHALI-01临床试验1期阶段中开发，用于治疗复发/难治性非霍奇金淋巴瘤患者[2] - 第二项海报强调在BALLI-01试验1期阶段中，接受lasme-cel治疗的难治患者体内阿仑单抗暴露量与反应深度之间的相关性，该试验测试这种靶向CD22的同种异体CAR-T产品候选物，用于治疗复发/难治性急性淋巴细胞白血病[5] 产品候选物eti-cel数据 - eti-cel的初步结果显示，在当前剂量水平下，总缓解率为86%，完全缓解率为57%（n=7），7名患者中有4名达到完全缓解[3] - 临床前数据表明，将eti-cel与低剂量白细胞介素-2联合使用，可能加深并延长复发/难治性非霍奇金淋巴瘤患者的抗肿瘤活性[2] - 公司预计将在2026年公布eti-cel的完整1期数据集，包括低剂量IL-2联合队列的数据[3] 产品候选物lasme-cel数据 - 数据确定了一个阿仑单抗的阈值暴露水平，高于该水平则更有可能实现完全缓解/伴不完全血液学恢复的完全缓解，且不会增加毒性[5] - 这些数据证实了阿仑单抗在优化这些经过大量预治疗的患者反应方面的关键作用，并表明可以进一步提高在1期项目中观察到的高CR/CRi和微小残留病阴性率[6] - 公司关键性2期项目预计将于2025年第四季度开始招募患者[6] 公司业务概览 - 公司是一家临床阶段的生物技术公司，利用其开创性的基因编辑平台开发挽救生命的细胞和基因疗法[8] - 公司在肿瘤领域采用同种异体方法开发CAR-T免疫疗法，开创了即用型基因编辑CAR-T细胞治疗癌症患者的概念[8] - 凭借其内部制造能力，公司是少数几家能够从头到尾控制细胞和基因治疗价值链的端到端基因编辑公司之一[8]

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https://www.cellect ...

美股期指及Olema Pharmaceuticals股价异动 - 美股期指今日早盘走高，道指期指上涨约0.2% [1] - Olema Pharmaceuticals股价在盘前交易中下跌18.3%至7.64美元，原因是公司公布了palazestrant联合ribociclib用于ER+/HER2-转移性乳腺癌的1b/2期试验新数据 [1] 其他盘前下跌个股 - Concord Medical Services股价下跌24.4%至4.15美元，此前周五已下跌6% [3] - Addex Therapeutics股价下跌15.6%至9.23美元，此前周五上涨28% [3] - Exelixis股价下跌8.3%至36.00美元，原因是公司公布了评估zanzalintinib联合免疫检查点抑制剂治疗转移性结直肠癌的3期STELLAR-303关键试验的详细结果 [3] - Cellectis股价下跌7.3%至3.69美元 [3] - Alumis股价下跌6.7%至4.19美元 [3] - Nanobiotix股价下跌6.3%至23.98美元，此前周五已下跌4% [3] - Genmab股价下跌4.1%至31.81美元，尽管其Rinatabart Sesutecan在晚期子宫内膜癌中达到50%的客观缓解率并获得两个完全缓解 [3] - Taysha Gene Therapies股价下跌4%至4.53美元 [3]

○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months ○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status ○ In the target Phase 2 population, 100% patients became transplant eligibl ...

 ○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months ○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status ○ In the target Phase 2 population, 100% patients became transplant eligibl ...

Cellectis (NasdaqGM:CLLS) 2025 Investor Day October 16, 2025 08:30 AM ET Speaker0can say also it's like the event will end up at 10:30. So with that, I would like to So PLL is definitely on on Metmedical. First of all, there's roughly ten thousand patient worldwide, not worldwide, in The US, EU4 and The UK on a yearly basis. And most of the time, these patients are treated by chemotherapy as the first one. We have a heavy relapse rate for essentially.ABCs have definitely an effect, but it's limited effect t ...

公司研发活动 - 公司于2025年10月16日在纽约市举办研发日活动 [1] - 活动时间为美国东部时间08:30至10:30，形式包括现场参与和网络直播 [4] 核心产品管线进展 - 公布了lasme-cel（UCART22）治疗复发或难治性B细胞急性淋巴细胞白血病（r/r B-ALL）的完整1期临床试验数据集 [1] - 概述了针对该适应症的关键性2期临床试验设计方案 [1] - 公司领导团队和关键意见领袖将介绍该产品的商业机会 [1] 公司业务模式与技术平台 - 公司是一家临床阶段的生物技术公司，利用其开创性基因编辑平台开发细胞和基因疗法 [2] - 公司在肿瘤治疗领域采用同种异体方法开发CAR-T免疫疗法，开创了即用型、经基因编辑的CAR-T细胞治疗癌症患者的理念 [2] - 公司拥有内部制造能力，是少数几家能够控制从始至终的细胞和基因疗法价值链的端到端基因编辑公司之一 [2] - 公司总部位于法国巴黎，在纽约和北卡罗来纳州罗利设有办事处，在纳斯达克全球市场和泛欧交易所创业板上市 [2]

公司事件 - 癌症药物开发商Allogene Therapeutics宣布其许可方Cellectis在美国面临专利侵权诉讼 [2] - 诉讼指控与基因编辑技术相关的专利侵权 [2] - 该信息通过监管文件披露 [2]

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that findings highlighting the strong potential of circular single-stranded DNA (CssDNA) as a universal, efficient non-viral template for gene therapy, along with a comprehensive study of TALE base editors (TALEB) off-targets in the nuclear genome, will b ...